Source link : https://www.newshealth.biz/health-news/finerenone-benefits-heart-failure-with-preserved-ef/
LONDON — The benefit of mineralocorticoid receptor antagonists (MRAs) for the treatment of patients with heart failure and mildly reduced or preserved ejection fraction has finally been established in the FINEARTS-HF trial. Full trial results show that finerenone, a third-generation nonsteroidal MRA, reduced the primary endpoint of worsening heart failure events (unplanned hospitalization or urgent […]
Author : News Health
Publish date : 2024-09-03 19:21:25
Copyright for syndicated content belongs to the linked Source.